Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine, but with unusual ...

A new COVID-19 vaccine has been approved, but it's not available to everyone. Aerial drone footage shows the humpback whale (Megaptera novaeangliae) missing its iconic lobed fluke, which is ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots.

Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is ...